Discounted tuition offered for EMS training in Louisiana
BATON ROUGE, La. (Louisiana First) — Emergency medical technicians are in high demand nationwide. The National EMS Academy, a sister company of Acadian Ambulance, is cutting tuition to make it more affordable.
Tuition for the 12-week class is usually $1,900, but it is being discounted 78% off to only $400 for a limited time at many Louisiana training centers, including Baton Rouge, Covington, New Orleans and Thibodaux.
Once students pass the class and national registry exam, they will be eligible to work at Acadian Ambulance locations in Texas, Louisiana, Mississippi, and Tennessee.
Recruiters said applicants will be allowed to put the $400 on a payment plan. Click here for registration, which is now open for classes starting on June 2.
Inflation rose in April, reversing March decline
NFL player hosting football camp in Baton Rouge
Schumer places hold on DOJ political nominees over Qatari jet gift to Trump
Report suggests new coordinating entity for East Baton Rouge early childhood education
Discounted tuition offered for EMS training in Louisiana
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Kansas faces $3.77B in Medicaid cuts, thousands to lose coverage under Trump's bill: report
KANSAS CITY, Mo. — Kansas will lose more than $3 billion in Medicaid funding, and thousands of Kansans will lose access to health insurance under Trump's proposed bill, according to a new report. New modeling shows 13,000 fewer Kansans would be able to enroll in Medicaid under the 'One Big Beautiful Bill' recently passed by the U.S. House, and the state would lose $3.77 billion in total Medicaid funding. Man charged in death of Platte County sports reporter shot on I-29 The modeling showed $2.29 billion in lost federal Medicaid funding alone—and $3.77 billion when combined with associated state funding losses over a 10-year period. Such losses would likely lead to higher uninsured rates and more financial struggles for rural hospitals already on the brink of closure. These results were recently released by Manatt Health, which conducted the analysis at the request of Kansas health philanthropies United Methodist Health Ministry Fund and REACH Healthcare Foundation. The two organizations wanted to better understand the financial and enrollment impacts of the bill, which would cut $700 billion from Medicaid and is awaiting a vote in the Senate. Medicaid, the public health insurance program that covers more than 366,000 Kansans, is funded jointly by the state and federal government. It provides low-income parents, children, seniors and people with disabilities with health insurance. Adults who do not have children do not qualify for Medicaid in Kansas. 'If this bill passes, it will cause long-lasting harm to thousands of families across Kansas and seriously threaten the survival of rural hospitals across the state,' said Brenda Sharpe, president and CEO at REACH Healthcare Foundation. The analysis shows Kansas will face significant coverage losses and funding reductions over the next 10 years. Manatt said the losses are even greater than shown in the analysis, as data limitations made it unable to model all the provisions in the bill. The estimates do not account for prohibitions on states setting up any new provider taxes or increasing assessments for other providers. That will cause Kansas health care providers, including nursing homes and other health providers, to lose critical funding over time and cause them to become even more financially vulnerable, Manatt said in a news release Wednesday. Coverage losses due to the bill's changes to the Affordable Care Act's Health Insurance Marketplace also couldn't be modeled. However, they will result in additional Kansans losing health insurance, according to Manatt. Not only will the bill remove people's health insurance, it also will remove food assistance. The bill includes $300 billion in cuts from the Supplemental Nutrition Assistance Program (SNAP). 'Congress is trying to rush a plan through the process that will take health care and food assistance away from tens of thousands of Kansans, including children, seniors and people with disabilities,' said David Jordan, president and CEO at the Health Fund. 'At a time when hospitals are trying to keep their doors open and working families are struggling to keep a roof over their heads and food on their tables, we cannot afford these cuts.' Kansas already has more hospitals at risk of closure than any other state in the country. A recent report from the University of Kansas School of Nursing highlights the growing 'maternal care desert' in Kansas. Manatt said 63 rural hospitals are currently at risk, and 87% of Kansas rural hospitals are operating in the red. These hospitals struggle to survive with existing federal funding – and provisions in the bill would cause them to lose billions, making it even harder to stay open. When rural hospitals close, it removes job opportunities and access to health care, creating a ripple effect in small communities, Manatt said. You can read the full report below or by clicking here. Medicaid-Cut-Impacts-to-KansasDownload Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential. Tessa Romero, an analyst at JPMorgan, has maintained her Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) but reduced the firm's price objective from $71 to $53. A lab technician using a microscope to examine the biopharmaceutical company's molecules. Aficamten's revised revenue projections, which anticipate a slower launch trajectory, are the basis for the modification. The management's latest remarks, which reflect the Camzyos launch pace for obstructive hypertrophic cardiomyopathy (oHCM), are consistent with this reevaluation. According to JPMorgan, expectations for adoption will be significantly influenced by the final medicine label. Cytokinetics, Incorporated (NASDAQ:CYTK) experimental treatment for oHCM, Aficamten, is still a valuable tool with promising clinical outcomes. Although JPMorgan admits that the launch trajectory was slower than anticipated, the company is still confident in the drug's unique profile when compared to Camzyos, especially with regard to pharmacology, safety, and dosing flexibility. These qualities and corroborating evidence support JPMorgan's assessment of aficamten's acceptability. The lower price objective is not a reflection of a shift in opinion about the drug's strategic worth or efficacy, but rather of modified commercial ramp assumptions. It is a late-stage biopharmaceutical business that focuses on discovering, developing, and bringing to market first-in-class muscle activators and next-in-class muscle inhibitors as possible cures for fatal diseases where muscle function is impaired or deteriorating. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
